Epigenetic clocks of biological aging and risk of incident mild cognitive impairment and dementia: the Women's Health Initiative Memory Study
Nguyen, S.; Lu, A.; Horvath, S.; Espeland, M.; Rapp, S. R.; Maihofer, A. X.; Nievergelt, C. M.; LaCroix, A. Z.; Mcevoy, L. K.; Resnick, S. M.; Beckman, K. B.; Shadyab, A. H.
Show abstract
Aging is the strongest risk factor for dementia; however, few studies have examined the association of biological aging with incident dementia. We analyzed 6,069 cognitively unimpaired women (mean age=70.0 {+/-} 3.8 years) in the Womens Health Initiative Memory Study to examine the association of accelerated biological aging, measured with second and third-generation epigenetic clocks (AgeAccelPheno and AgeAccelGrim2, and DunedinPACE, respectively) with incident mild cognitive impairment (MCI) and probable dementia. Multivariable Cox proportional hazards models adjusted for age, race, ethnicity, smoking, hormone therapy regimen, physical activity, body mass index, and estimated white blood cell counts. For comparison, we also examined first-generation epigenetic clocks (AgeAccelHorvath; AgeAccelHannum). We evaluated effect modification by age, race/ethnicity, hormone therapy regimen, menopause type (natural vs surgical), and APOE {varepsilon}4 carriage. There were 1,307 incident MCI or probable dementia events over a median follow-up of 9.3 (25th percentile=6.1, 75th percentile=16.1) years. The adjusted HRs (95% CI; p-value) for incident MCI/probable dementia per one-standard deviation increment were 1.07 (1.01-1.15; p=0.03) for DunedinPACE, 1.11 (1.02-1.20; p=0.01) for AgeAccelGrim2, and 1.01 (0.95-1.07; p=0.74) for AgeAccelPheno. Only AgeAccelGrim2 was significant under the Bonferroni-corrected threshold for significance (p<0.02). Other epigenetic clocks were not associated with incident MCI/probable dementia. There was no effect modification in subgroup analyses (all P-interaction generally [≥] 0.05). In this cohort study of older women, accelerated biological aging measured by AgeAccelGrim2 was associated with higher risk of incident MCI/probable dementia. These findings provide evidence linking epigenetic biomarkers of biological aging with development of MCI and dementia independent of chronological age.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Quantification of the pace of biological aging in humans through a blood test: The DunedinPoAm DNA methylation algorithm 95%
- Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration stratified by sex 94%
- The effect of 18 months lifestyle intervention on brain age assessed with resting-state functional connectivity 94%
Similar papers in this journal
- Association between telomere length and cognitive function among cognitively unimpaired individuals at risk of Alzheimer’s disease 95%
- Cerebrovascular response to exercise interacts with individual genotype and amyloid-beta deposition to influence response inhibition with aging 94%
- Subtypes of brain change in aging and their associations with cognition and Alzheimer's disease biomarkers 94%
Similar papers in this journal
Similar papers in this journal
- A meta-analysis of brain DNA methylation across sex, age and Alzheimer’s disease points for accelerated epigenetic aging in neurodegeneration 93%
- High blood uric acid is associated with reduced risks of mild cognitive impairment among older adults in China: a 9-year prospective cohort study 93%
- Lower Hippocampal Volume Partly Mediates the Association Between rs6859 in the NECTIN2 Gene and Alzheimer's Disease: New Findings from Causal Mediation Analysis of ADNI Data 92%